BC Cancer’s Leukemia and Myeloma Program (LaMP) launches, uncovering more effective treatments for people in B.C.
Thanks to support from BC Cancer Foundation donors, BC Cancer has launched a new Leukemia and Myeloma Program (LaMP), which seeks to uncover more effective diagnostic and treatment solutions for people affected by blood cancers.
- REVOLUTIONIZING MULTIPLE MYELOMA TREATMENT
BC Cancer Clinician-Scientist Dr. Florian Kuchenbauer and his team aim to increase multiple myeloma survival rates: “Our goal is to better understand the evolution of myeloma, especially high-risk myeloma and how it becomes resistant to treatment,” Dr. Kuchenbauer explains. “We plan to test and combine drugs in new ways and eventually launch clinical trials to give more choices to patients.”
- UNDERSTANDING THE BIOLOGY OF BLOOD CANCERS
BC Cancer Distinguished Scientist Dr. Andrew Weng and his team discovered that while adult and childhood leukemia cells are similar, both can be re-programmed to a state in which the leukemia stem cells exhaust themselves, resulting in the disappearance of disease. “We believe a new class of drugs may improve outcomes for people facing T-cell acute lymphoblastic leukaemia who fail conventional therapies,” says Dr. Weng.
- IMPROVING OUTCOMES FOR ACUTE MYELOID LEUKEMIA
Relapse following chemotherapy or stem cell transplantation is the most frequent cause of death in people with acute myeloid leukemia (AML). “We just launched a project to define what causes resistance and find ways to overcome this resistance,” says Dr. Aly Karsan, BC Cancer distinguished scientist. “By creating AML models in the lab, we hope to find new ways to target leukemia that will spare healthy cells and give people a better chance at survival.”